13,000 Shares in Arbutus Biopharma Co. (NASDAQ:ABUS) Bought by Helen Stephens Group LLC

Helen Stephens Group LLC purchased a new position in shares of Arbutus Biopharma Co. (NASDAQ:ABUS) in the 3rd quarter, HoldingsChannel reports. The institutional investor purchased 13,000 shares of the biopharmaceutical company’s stock, valued at approximately $50,000.

Several other hedge funds have also recently modified their holdings of the stock. SG Americas Securities LLC acquired a new stake in shares of Arbutus Biopharma during the third quarter worth $204,000. Susquehanna Fundamental Investments LLC raised its position in Arbutus Biopharma by 102.2% in the second quarter. Susquehanna Fundamental Investments LLC now owns 208,152 shares of the biopharmaceutical company’s stock worth $643,000 after acquiring an additional 105,228 shares in the last quarter. The Manufacturers Life Insurance Company raised its position in Arbutus Biopharma by 7.9% in the second quarter. The Manufacturers Life Insurance Company now owns 57,323 shares of the biopharmaceutical company’s stock worth $177,000 after acquiring an additional 4,191 shares in the last quarter. Bank of Montreal Can raised its position in Arbutus Biopharma by 6.1% in the second quarter. Bank of Montreal Can now owns 354,813 shares of the biopharmaceutical company’s stock worth $1,100,000 after acquiring an additional 20,548 shares in the last quarter. Finally, Rubric Capital Management LP purchased a new position in Arbutus Biopharma in the second quarter worth $5,195,000. 43.79% of the stock is owned by institutional investors and hedge funds.

Arbutus Biopharma Stock Performance

Shares of ABUS stock opened at $3.77 on Wednesday. Arbutus Biopharma Co. has a fifty-two week low of $1.69 and a fifty-two week high of $4.72. The business has a fifty day simple moving average of $3.94 and a 200-day simple moving average of $3.40.

Arbutus Biopharma (NASDAQ:ABUS) last announced its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.01). The firm had revenue of $1.73 million during the quarter, compared to analysts’ expectations of $1.54 million. Arbutus Biopharma had a negative net margin of 766.20% and a negative return on equity of 66.68%. During the same quarter in the prior year, the business earned ($0.10) EPS. On average, sell-side analysts expect that Arbutus Biopharma Co. will post -0.38 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on ABUS shares. StockNews.com upgraded Arbutus Biopharma from a “sell” rating to a “hold” rating in a research report on Saturday, August 10th. JMP Securities increased their price objective on Arbutus Biopharma from $4.00 to $5.00 and gave the stock a “market outperform” rating in a research report on Friday, August 2nd. Finally, Jefferies Financial Group increased their price objective on Arbutus Biopharma from $5.00 to $7.00 and gave the stock a “buy” rating in a research report on Thursday, September 5th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $5.25.

Arbutus Biopharma Company Profile

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.